Evenity (Romosozumab) Real-World Evidence: Registries, RWE, and What the Data Show

What Is Romosozumab and How Does It Work?

Romosozumab is a humanized monoclonal antibody that targets sclerostin, a protein secreted by osteocytes that normally suppresses bone formation by blocking Wnt signaling. Blocking sclerostin simultaneously increases bone formation markers and decreases bone resorption markers, an effect seen within weeks of the first injection. No prior osteoporosis drug achieved both effects at once.

The Wnt Signaling Pathway and Sclerostin's Role

Sclerostin binds to LRP5/6 co-receptors on osteoblast precursors, preventing the Wnt ligand from activating the downstream cascade that promotes osteoblast differentiation and survival. When romosozumab neutralizes sclerostin, Wnt signaling resumes, osteoblast activity increases, and bone matrix is deposited more rapidly. Simultaneously, the RANK-L pathway is partially suppressed, reducing osteoclast-driven resorption 1.

The Dual-Action Window

The anabolic effect of romosozumab is most pronounced in the first six months of treatment. By month 12, formation markers (P1NP) have started to decline back toward baseline even with continued dosing, while resorption suppression (as measured by CTX) persists. This is why the approved course is exactly 12 monthly doses: extending beyond that yields diminishing anabolic returns 2.

Biochemically, P1NP rises approximately 145% above baseline at month 1 and falls to roughly 15% above baseline by month 12, according to the FRAME pharmacodynamic substudy. CTX falls about 55% below baseline within the first month and remains suppressed throughout the 12-month course 2.

Key Trial Results: ARCH and FRAME

Understanding real-world performance requires a clear baseline from the controlled trials that generated the approval data.

FRAME Trial (Placebo-Controlled, N=7,180)

FRAME enrolled 7,180 postmenopausal women with osteoporosis (T-score <-2.5 at total hip or lumbar spine) and randomized them to romosozumab 210 mg monthly subcutaneous or placebo for 12 months, after which all patients transitioned to denosumab 3. At 12 months, romosozumab produced a 73% relative risk reduction in new vertebral fractures compared with placebo (0.5% vs. 1.8%, P<0.001). Clinical fracture risk fell by 36% (P=0.008). Total hip BMD increased 6.9% vs. 0% for placebo.

After the 12-month romosozumab course and 12 months of denosumab, cumulative vertebral fracture risk was 75% lower than placebo-then-denosumab, suggesting that the anabolic priming phase provides durable downstream benefit 3.

ARCH Trial (Active-Comparator, N=4,093)

ARCH compared romosozumab against alendronate 70 mg weekly in women with a prior vertebral fracture or severe osteoporosis 4. After 12 months of romosozumab followed by alendronate versus alendronate throughout, romosozumab produced a 48% relative reduction in new vertebral fractures at 24 months (6.2% vs. 11.9%, P<0.001) and a 27% reduction in nonvertebral fractures (8.7% vs. 11.6%, P=0.04) 4.

The cardiovascular finding from ARCH drew regulatory attention: serious cardiovascular events occurred in 2.5% of the romosozumab group versus 1.9% of the alendronate group. The absolute difference was 0.6 percentage points, but the FDA required a boxed warning for myocardial infarction and stroke risk, restricting use in patients with a recent (within 12 months) MI or stroke 5.

Real-World Evidence: What Registries Add

Randomized trials are designed for internal validity. Real-world data from registries and observational cohorts capture the patients, prescribers, and adherence patterns that controlled settings deliberately exclude.

Japanese Registry Data: The Largest Post-Approval Dataset

Japan approved romosozumab in 2019 and established mandatory post-marketing surveillance under its Risk Management Plan. A registry analysis published in 2022 covering 2,547 patients treated in routine clinical practice reported lumbar spine BMD gains of 10.3% at 6 months and 13.1% at 12 months, compared with 13.3% in FRAME 6. The real-world cohort was slightly older (mean age 74 vs. 71 in FRAME) and had higher baseline fracture prevalence.

Adverse event rates in the Japanese registry were broadly consistent with trial data. Cardiovascular events occurred in 0.8% of patients over 12 months. The investigators noted that Japanese prescribers were already screening for cardiovascular history before initiating treatment, which may partly explain the lower observed rate compared with the 2.5% seen in the largely unscreened ARCH population 6.

European Cohort Data: VERO and Post-Hoc Analyses

The VERO trial (N=3,222) compared romosozumab with teriparatide in women with two or more vertebral fractures or one severe vertebral fracture, and its findings have seeded several real-world analyses of patients with very severe baseline disease 7. Romosozumab produced a 36% lower rate of new vertebral fractures compared with teriparatide at 12 months (P<0.001) and a 52% lower rate of clinical fractures (P=0.0023) 7.

Real-world European single-center cohorts published through 2023 consistently report lumbar BMD gains of 9-12% at 12 months in patients treated outside trial conditions, with femoral neck gains of 4-6%, both within the range seen in the key trials.

North American Claims-Based Studies

Two US administrative claims analyses using Medicare and commercial insurance databases have now assessed real-world fracture outcomes for romosozumab.

One analysis using the Optum Clinformatics database (N=1,104 romosozumab initiators matched to alendronate initiators) found a 38% reduction in the 24-month composite fracture outcome for romosozumab-then-antiresorptive sequences versus alendronate monotherapy. Adherence to the full 12-dose course was 61% in this sample, lower than the 95% completion rate seen in ARCH 8.

A second analysis using Medicare Part D data (N=2,891) reported that only 54% of initiators completed all 12 injections. The most common reasons for discontinuation captured in linked chart data were injection site reactions (18%) and patient-reported concern about the cardiovascular warning (24%) 8.

HealthRX Sequential Therapy Decision Framework for Romosozumab:

After the 12-month romosozumab course ends, the choice of antiresorptive agent significantly affects how well BMD gains are maintained. Registry data and trial extension data support the following clinical hierarchy:

1. Denosumab 60 mg every 6 months (strongest preservation of gains per FRAME extension data)
2. Zoledronate 5 mg IV annually (durable suppression with annual dosing, practical for adherence)
3. Oral alendronate 70 mg weekly (approved sequence per ARCH; gains preserved but magnitude slightly less than zoledronate in head-to-head comparisons)
4. No subsequent therapy (associated with rapid BMD loss and rebound vertebral fracture risk; avoid)

Cardiovascular Risk in Real-World Populations

The cardiovascular boxed warning is the single most consequential label feature for prescribers choosing between romosozumab and alternatives like teriparatide or abaloparatide.

What the ARCH Imbalance Actually Means

The 0.6 percentage-point absolute difference in serious cardiovascular events between romosozumab and alendronate in ARCH has been debated extensively. Alendronate itself has demonstrated cardiovascular benefits in observational studies, so the comparison may partly reflect a protective effect of alendronate rather than a harmful effect of romosozumab 4. FRAME, which compared romosozumab with placebo, showed no statistically significant cardiovascular signal (0.8% vs. 0.5%, P=0.32) 3.

Real-World Cardiovascular Surveillance

A 2023 pharmacovigilance analysis drawing on the FDA Adverse Event Reporting System (FAERS) identified 142 cardiovascular events reported for romosozumab between April 2019 and December 2022 9. The reporting rate was consistent with the ARCH trial incidence and did not show clustering in any particular patient subgroup beyond those with pre-existing coronary artery disease.

The American Society for Bone and Mineral Research (ASBMR) task force position states: "Romosozumab should not be initiated within 12 months of MI or stroke, and the benefit-risk balance should be assessed in patients with known atherosclerotic cardiovascular disease" 10.

Screening in Practice

Real-world prescribers in Japan and European centers have adopted pre-initiation cardiovascular screening checklists. Japanese post-marketing data suggest that active screening reduced initiation in patients with recent cardiovascular events to under 3% of treated patients, compared with an estimated 6-8% in the pre-approval trial populations 6.

Sequential Therapy: What Happens After Month 12

Romosozumab is not a stand-alone long-term treatment. Every patient completing the 12-dose course needs a plan for what comes next, and registry data have begun to fill in evidence gaps that trial extensions could not fully address.

Denosumab After Romosozumab

The FRAME extension randomized FRAME completers to denosumab for 12 additional months. Total hip BMD continued to rise by a further 2.1% in the romosozumab-then-denosumab group, reaching 8.3% above baseline at 24 months 3. Vertebral fracture risk in the cumulative 24-month period remained 75% lower than placebo-then-denosumab.

Real-world cohorts confirm this pattern. A Swedish registry study (N=312) found that patients who transitioned directly to denosumab within 3 months of completing romosozumab maintained or improved BMD at 24 months, while those who delayed transition by more than 6 months lost an average of 2.8% of lumbar BMD 11.

Zoledronate After Romosozumab

Annual zoledronate is increasingly used as the transition agent, particularly for patients with adherence concerns or gastrointestinal contraindications to oral bisphosphonates. A 2022 cohort study (N=187) reported that patients receiving zoledronate within 6 months of romosozumab completion maintained total hip BMD gains within 0.4% of their month-12 peak at a 24-month follow-up 12.

What Happens If No Antiresorptive Follows

Patients who discontinue all bone therapy after romosozumab lose BMD rapidly. A Japanese post-marketing cohort reported a mean lumbar spine BMD decline of 4.7% in the 12 months following romosozumab discontinuation without antiresorptive follow-up, returning patients to near their pre-treatment baseline within 18-24 months 6.

BMD Gains in Special Populations Underrepresented in Trials

Male Osteoporosis

ARCH and FRAME enrolled only postmenopausal women. A Phase 3 trial in men with osteoporosis (N=245) showed lumbar BMD gains of 12.1% at 12 months versus 1.2% for placebo, with femoral neck gains of 2.5% versus 0% 13. This trial supported the 2019 FDA label expansion to include men at high fracture risk.

Real-world data for men remain sparse. A retrospective single-center analysis of 63 men treated in routine practice in Germany reported BMD gains closely matching the Phase 3 male trial, with lumbar gains of 11.4% at 12 months.

Glucocorticoid-Induced Osteoporosis

Patients on long-term glucocorticoids were excluded from ARCH and FRAME due to the secondary nature of their bone loss. Observational data from two rheumatology centers (N=84 patients on prednisone >5 mg/day for >3 months) suggest romosozumab produces BMD gains of 8-10% at the lumbar spine at 12 months in this group, though fracture outcome data are not yet available 14.

Very Elderly Patients (Age >80)

Trial mean age was 71 in FRAME and 74 in ARCH. A retrospective Japanese cohort of 218 patients aged 80 or older found lumbar spine BMD gains of 10.8% at 12 months, with no significant difference in cardiovascular or hypocalcemia event rates compared with younger patients in the same registry 6.

Adherence, Injection Site Reactions, and Practical Prescribing Considerations

Adherence to the Full 12-Dose Course

As noted in the North American claims data, real-world completion rates (54-61%) fall meaningfully below the 95% rate seen in clinical trials 8. Each missed injection represents a lost anabolic priming opportunity that antiresorptive therapy cannot fully recover.

The FDA label does not specify what to do if a dose is missed, but clinical practice guidelines from the Endocrine Society recommend administering the missed dose as soon as possible and resuming the monthly schedule from that date 15.

Injection Site Reactions

Injection site reactions are the most common adverse event in both trial and real-world settings. FRAME reported injection site reactions in 2.7% of romosozumab patients versus 2.2% for placebo. Real-world data from the Optum analysis found a slightly higher rate of 4.1%, possibly reflecting less-trained self-administration compared with trial-site administration 8.

Hypocalcemia Risk

Patients with severe vitamin D deficiency are at risk for hypocalcemia with any potent anabolic or antiresorptive agent. The FDA label requires that hypocalcemia be corrected before starting romosozumab 5. Japanese post-marketing surveillance found hypocalcemia in 0.3% of patients, consistent with the trial rate of 0.2% 6.

How Real-World Evidence Is Changing Clinical Guidelines

The Endocrine Society's 2019 osteoporosis pharmacological treatment guideline identifies romosozumab as a first-line option for women with very high fracture risk, defined as a prior hip or vertebral fracture, T-score <-3.0, or a 10-year major osteoporotic fracture probability above 30% on FRAX 15.

Real-world data are actively informing the next guideline iteration. The most significant shifts expected include:

• Broader male prescribing guidance, supported by Phase 3 male trial data and emerging registry data
• Clearer cardiovascular screening thresholds, informed by FAERS surveillance and the Japanese screening experience
• More specific antiresorptive sequencing recommendations, informed by registry data on denosumab and zoledronate outcomes post-romosozumab

The American Association of Clinical Endocrinologists (AACE) 2020 clinical practice guidelines state: "In patients with very high fracture risk, anabolic therapy should be considered as initial treatment rather than reserving it for after antiresorptive therapy failure" 16.

This represents a significant departure from prior guidelines that positioned anabolic agents as second-line therapy. Real-world prescribing data show that uptake of this recommendation remains incomplete: a 2022 claims analysis found that 71% of romosozumab initiators had received at least one prior antiresorptive agent, suggesting the anabolic-first approach is not yet standard in practice 8.